Chemical Properties:
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.Manufacturer Supply with High Purity and Stable Quality Chemical Name: Abacavir CAS: 136470-78-5 A powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. API High Quality, Commercial Production| Item | Specifications |
| Appearance | White to Off-White Crystalline Powder |
| Identification | (1) IR (2) HPLC (3) Sulfate |
| Water | ≤0.50% |
| Residue on Ingnition | ≤0.20% |
| Limit of the Abacavir Enantiomer | ≤0.20% |
| 1) Related Substances | |
| Descyclopropyl Abacavir | ≤0.20% |
| Trans-Abacavir | ≤0.20% |
| O-Pyrimidinyl Abacavir | ≤0.20% |
| t-Butyl Derivate Abacavir | ≤0.20% |
| Any Unspecific Impurity | ≤0.10% |
| Total Impurities | ≤0.80% |
| 2) Enantiomeric Purity | Abacavir Enantiomer ≤0.20% |
| 3) Residual Solvents | |
| Methanol | ≤0.30% |
| Acetone | ≤0.50% |
| Ethanol | ≤0.50% |
| Heavy Metals | ≤20ppm |
| Assay | 99.0%~101.0% (calculated on anhydrous and solvent free basis) |
| Test Standard | United States Pharmacopeia (USP) Standard |
| Usage | API; anti-HIV |
Description:
Specifications:
Package & Storage:
| Chemical Name | Abacavir |
| CAS Number | 136470-78-5 |
| CAT Number | RF-API62 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C14H18N6O |
| Molecular Weight | 286.33 |
| Melting Point | 165℃ |
| Shipping Condition | Under Ambient Temperature |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Abacavir (CAS: 136470-78-5) with high quality. Abacavir API is a carbocyclic 2'-deoxyguanosine nucleoside reverse transcriptase inhibitor (NRTI) and an anti-HIV drug used to treat HIV infection. NRTIs work by blocking HIV reverse transcriptase, an HIV enzyme. This product is intended for the treatment of adults infected with human immunodeficiency virus (HIV). Three fixed components (Abacavir, Lamivudine, and Zidovudine) are used in lieu of three monotherapies at similar doses. Abacavir, Lamivudine, and Zidovudine alone are recommended for 6-8 weeks at the beginning of treatment.
